[/toggle]

Teva Pharmaceutical Industries (TEVA) gave a bullish outlook on its generics business. The company expects the unit to generate $14 billion to $15 billion in sales this year.

The company also said that it now wants to get U.S. approval for generic version of Mylan’s (MYL) EpiPen. EpiPen has come under scrutiny because of Mylan’s decision to hike the price of injection by 400% since acquiring it almost 10 years ago.

Achillion and Janssen’s Triple Combination Therapy Achieves 100% Cure Rate in HCV-1- Janssen (JNJ) announced interim results from a Phase 2a trial evaluating a tripe combination therapy for the treatment of HCV. The results showed a 100% cure rate in as little as six weeks. The data will be presented at the European Association for the Study of the Liver Special Conference in Paris, September 23 - 24. The 20 subjects in cohort 1 received a daily dose of the combination of odalasvir (50 mg), AL-335 (400 mg) and simeprevir (100 mg) for eight weeks. All achieved clinical cure 24 weeks after completed therapy (SVR24). The 20 patients in cohort 2 received 800 mg of AL-335 every day and 50 mg of odalasvir every other day for eight weeks. The cure rate at 12 weeks post treatment (SVR12) was 90%. The 20 subjects in cohort 3 received 800 mg of AL-335 and 75 mg of simeprevir every day and 50 mg of odalasvir every other day for eight weeks. All achieved clinical cure four weeks after the end of therapy (SVR4). The 20 subjects in cohort 4 received the same regimen as cohort 3 but for only six weeks. HCV RNA was negative in 90% (n=18/20) and the other two were below the limit of quantitation at the end of treatment. AL-335 is a uridine-based nucleoside NS5B polymerase inhibitor being developed by Janssen unit Alios BioPharma. Odalasvir (formerly ACH-3102) is an NS5A inhibitor discovered by Achillion Pharmaceuticals (ACHN).

Lexicon’s Sotaglifozin Succeeds In Late-Stage Study- Lexicon Pharmaceuticals (LXRX) announced positive results in a 793-subject Phase 3 clinical trial, Tandem1, evaluating orally-administered sotagliflozin in type 1 diabetics. The study met its primary endpoint of a statistically valid reduction in HbA1c at Week 24 on a background of optimized insulin. Top-line data showed patients treated with a daily dose of 200 mg of sotagliflozin experienced a mean reduction in HbA1c from baseline of 0.43% compared to a reduction of 0.08% for placebo (p<0.001). Patients treated with 400 mg of sotagliflozin once daily experienced a mean reduction of 0.49% (p<0.001).

Auris Medical Makes Progress With Development of AM-111- Auris Medical (EARS) announced that it has reached the enrollment mid-point in its 255-subject Phase 3 study, HEALOS, evaluating AM-111 for the treatment of idiopathic sudden sensorineural hearing loss (sudden deafness). The company also reiterated its expectation that top-line results will be available in H2 2017. A second pivotal study, 300-subject ASSENT, was initiated in June. It is the same design as HEALOS, but with a Day 91 assessment of the primary endpoint of PTA. The estimated study completion date is June 2018.

No approvals to report.

No patents to report.

Cancer Genetics (CGIX) announced that it has entered into definitive agreements with institutional investors for the direct placement of 2.75M common shares at $2. For each share purchased, buyers will receive an unregistered five-year warrant to acquire 1/2 of a share of stock at $2.25.

Sage Therapeutics (SAGE) announced the pricing of its public offering of 4,402,515 shares of common stock at $39.75 per share. The gross proceeds from the offering total $175 million. Underwriters to the offering have been granted an option to purchase an additional 660,377 shares to cover for over-allotment if any.

Proteostasis Therapeutics (PTI) announced the pricing of its public offering of 5 million shares of common stock at $13 per share. Underwriters to the offering have been granted an additional 750,000 shares to cover for over-allotment if any.

CoLucid Pharmaceuticals (CLCD) announced the pricing of its public offering of 3.25 million shares of common stock at $20 per share. Underwriters to the offering have been granted an option to purchase an additional 487,500 shares to cover for over-allotment if any. Net proceeds from the offering are expected to total $60.6 million and will be used to fund the continued clinical development of lasmiditan.

No IPOs to report.

Peregrine Pharma (PPHM) announced its financial results for the first quarter of its fiscal year. The company reported revenue of $5.6 million. PPHM’s net loss for the quarter was $12.4 million.

Cellectis (CLLS) reported second-quarter revenue of euro 18.1 million, up 126.3% on a year-over-year basis. Non-GAAP EPS for the quarter was $0.23 per share, up 153.5% on a year-over-year basis.

Champions Oncology (CSBR) reported first-quarter loss of $0.15 per share. The company’s revenue for the quarter was $3.7 million, up 32.1% on a year-over-year basis.

No analysts ratings to report.

No insider buys to report.

No insider sells to report.

No management changes and additions to report.

No big movers to report.

Company (Ticker) Short Interest as a % of Float % Change Days to Cover
Aralez Pharmaceuticals (ARLZ)

4.5%

-3.9%

3

Arbutus Biopharma (ABUS)

4.1%

-6.8%

11

ARCA Biopharma (ABIO)

1.4%

-11.5%

13

Arcadia Bioscience (RKDA)

2.5%

-14.6%

11

Ardelyx (ARDX)

2.8%

-10.2%

12

Argos Therapeutics (ARGS)

12.1%

-6.8%

6

ArQule (ARQL)

0.2%

-33.7%

1

Array Biopharma (ARRY)

10%

-13.5%

5

Arrowhead Pharmaceuticals (ARWR)

18%

0.7%

15

Assembly Biosciences (ASMB)

0.9%

-28.3%

8